Arimidex 2 - Gen-Shi Laboratories

As the first non-steroidal aromatase inhibitor of its class to gain FDA approval, anastrozole entered the U.S. pharmaceutical market in 1995, created by Zeneca. Its design bypassed the estrogen receptor entirely, aiming instead to stop estrogen production at its origin point — the aromatase enzyme. This innovation aligned with growing concerns over tamoxifen’s risks, especially regarding endometrial cancer. Anastrozole’s clinical edge was fully confirmed in the ATAC trial, which redefined endocrine therapy for breast cancer.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Arimidex 2 by Gen-Shi Laboratories, consult with your doctor or healthcare professional.